Tear layer approach effective for dry eye
May 1, 2012
The tear layer approach is effective in the diagnosis and treatment of dry eye syndrome.
Modern Medicine Now
Use genetic testing with caution
May 1, 2012
Ophthalmologists should not order routine genetic tests for patients with common disorders like age-related macular degeneration until there are specific therapeutic interventions available to treat the disease based on the genetic information.
NSAIDs safe in select patients
May 1, 2012
Topical branded nonsteroidal anti-inflammatory drugs are safe to use in patients with evaporative dry eye syndrome and in those with meibomian gland dysfunction.
ARVO moves its annual meeting from Fort Lauderdale
May 1, 2012
Having the ARVO meeting in any of various locations enables the group to accommodate more program options and have a variety of hotel options nearby.
Treat, prevent dry eye prior to cataract surgery
May 1, 2012
It is vital to identify and prevent dry eye and blepharitis pre-surgery because these conditions can affect IOL calculations and more.
More supplies of counterfeit drug found
May 1, 2012
FDA investigators say counterfeit vials of Roche/Genentech's bevacizumab that have turned up in U.S. medical practices for the second time in 2 months have no active ingredient.
Challenges, opportunities arise
May 1, 2012
The world of glaucoma management in 2012 is feeling the impact of not only a variety of challenges, but also new opportunities.
Earlier intervention more effective
May 1, 2012
Many ophthalmologists may be dropping the ball when treating moderate dry eye, which could result in progression to more severe stages of disease.
Hyperosmolarity key to dry eye
May 1, 2012
Tear osmolarity is well correlated to visual function, and may also be a key marker of dry eye disease
Studies support targeting IOP
May 1, 2012
Results from randomized controlled clinical trials investigating populations covering the spectrum from ocular hypertension to advanced glaucoma provide clear evidence that for most patients, glaucoma is an IOP-sensitive optic neuropathy for which lowering IOP is effective in slowing or arresting progression.
